옵투스제약

131030KOSDAQ

55.0 / 100

Reference Date: 2026-09-08

Financial Score27.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Optus Pharma specializes in developing and producing ophthalmic treatments for conditions such as dry eye and glaucoma, establishing a strong presence in the domestic market with products like Tierlin Pi eye drops. The company plans to expand its annual production capacity of single-use eye drops to 830 million units by 2026 with a new factory, while also growing its CMO/CDMO and global business segments to expand internationally.

Number of Employees

250people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.84Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.61Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

7.36Industry Average 8.002.5Point

Below industry avg

Debt Ratio

0.27Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.1% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.7% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 5,730Won52-week high 19,26052-week low 4,900

1-month return3.0Point

1m -1.21% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14